Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for NewAmsterdam Pharma Co N.V (NAMS) over the last 5 years, with Dec 2024 value amounting to -$2.56.

  • NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) fell 238.89% to -$0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.05, marking a year-over-year increase of 8.89%. This contributed to the annual value of -$2.56 for FY2024, which is 19.07% down from last year.
  • As of FY2024, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) stood at -$2.56, which was down 19.07% from -$2.15 recorded in FY2023.
  • In the past 5 years, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) ranged from a high of -$0.71 in FY2020 and a low of -$3.81 during FY2021.
  • For the 3-year period, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) averaged around -$1.97, with its median value being -$2.15 (2023).
  • In the last 5 years, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) tumbled by 438.21% in 2021 and then skyrocketed by 68.77% in 2022.
  • Over the past 5 years, NewAmsterdam Pharma Co N.V's EPS (Weighted Average and Diluted) (Yearly) stood at -$0.71 in 2020, then crashed by 438.21% to -$3.81 in 2021, then soared by 68.77% to -$1.19 in 2022, then crashed by 80.67% to -$2.15 in 2023, then fell by 19.07% to -$2.56 in 2024.